Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PYGB | P11216 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14823585 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL13541601 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL12295742 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL15616403 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL12733141 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL12337162 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL13498558 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL16076955 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL20626631 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 | |
| SCHEMBL13541586 | 1.00 | ALDH1A1 (0.56) | ALDH1A1THRBMAPK1CD69SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346816-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | THERAPEUTIKOS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-9981059-B2 | Sugar chain-polypeptide complex | GLYTECH, INC. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20170119844-A1 | HEMOSTATIC PHARMACEUTICAL COMPOSITION | OTSUKA CHEMICAL CO., LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| WO-2016152980-A1 | OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE CONSTRUCT USING SAME, AND METHODS FOR PRODUCING THESE | 国立大学法人岐阜大学 | 2016-09-29 | — | — | WO | disclosed |
| US-20160129150-A1 | SUGAR CHAIN-POLYPEPTIDE COMPLEX | GLYTECH, INC. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-9215888-B2 | Nutritional composition made using isolated organic matter | DUOIBES, ALBERT R. | 2015-12-22 | — | — | US | disclosed |
| US-20150182549-A1 | METHOD FOR ENZYMATIC GLYCOSYLATION OF OLIGOSACCHARIDES FROM MAMMALIAN ANIMAL MILK | GLYCOM A/S (DK) | 2015-07-02 | — | — | US | disclosed |
| US-8974793-B2 | Methods and systems for inducing immunologic tolerance to non-self antigens | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2015-03-10 | — | — | US | disclosed |
| US-20130295163-A1 | NON-REDUCING END MODIFIED GLUCAN, METHOD FOR PRODUCING SAME, AND USE THEREOF | EZAKI GLICO CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-8431551-B2 | Nutritional composition made using isolated organic matter | DUOIBES, ALBERT R | 2013-04-30 | — | — | US | disclosed |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-8198419-B2 | Glycorandomization and production of novel erythromycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120021056-A1 | Methods and Systems for Inducing Immunologic Tolerance to Non-Self Antigens | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20110171319-A1 | NUTRITIONAL COMPOSITION MADE USING ISOLATED ORGANIC MATTER | DUOIBES, ALBERT R | 2011-07-14 | — | — | US | disclosed |
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | THORSON JON | 2011-05-26 | — | — | US | disclosed |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20070173438-A1 | [PSI[CH2NH]PG4] glycopeptide antibiotic analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | HSPA5, GBA1, SNCA | ALDH1A1 4027/4885THRB 3467/4885MAPK1 2264/4885 |
| US-20120021056-A1 | Methods and Systems for Inducing Immunologic Tolerance to Non-Self Antigens | CD47, CD74, HLA-C | ALDH1A1 3800/4885THRB 4450/4885MAPK1 2294/4885 |
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | ALDH1A1 1950/4885THRB 4071/4885MAPK1 4161/4885 |
| US-20160129150-A1 | SUGAR CHAIN-POLYPEPTIDE COMPLEX | IAPP, ENPEP, QPCTL | ALDH1A1 4182/4885THRB 3049/4885MAPK1 1901/4885 |
| US-20150182549-A1 | METHOD FOR ENZYMATIC GLYCOSYLATION OF OLIGOSACCHARIDES FROM MAMMALIAN ANIMAL MILK | GALE, SI, FUT6 | ALDH1A1 786/4885THRB 1340/4885MAPK1 3663/4885 |
| US-20070173438-A1 | [PSI[CH2NH]PG4] glycopeptide antibiotic analogs | RPN2, PA2G4, DDOST | ALDH1A1 4039/4885THRB 3301/4885MAPK1 4241/4885 |
| US-20230346816-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTION | ACE, ACE2, MAVS | ALDH1A1 1745/4885THRB 4270/4885MAPK1 3248/4885 |
| US-20170119844-A1 | HEMOSTATIC PHARMACEUTICAL COMPOSITION | F12, FGB, HABP2 | ALDH1A1 3078/4885THRB 3567/4885MAPK1 3851/4885 |
| US-20110171319-A1 | NUTRITIONAL COMPOSITION MADE USING ISOLATED ORGANIC MATTER | SLC25A11, FABP2, FABP4 | ALDH1A1 3048/4885THRB 4832/4885MAPK1 3828/4885 |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | NMT2, NMT1, NAMPT | ALDH1A1 2259/4885THRB 4386/4885MAPK1 4166/4885 |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | ALDH1A1 1797/4885THRB 4031/4885MAPK1 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.